Answers are grounded in this paper and cite their sources.
Multicentre cohort study demonstrates superior survival in acute myeloid leukaemia patients with double-mutant CEBPA bZIP in-frame mutations, indicating refined risk stratification for intensive...
Summary The 2022 European LeukemiaNet (ELN) recommendation redefined favourable‐risk CCAAT/enhancer binding protein alpha ( CEBPA )‐mutated acute myeloid leukaemia (AML) by in‐frame C‐terminal basic leucine zipper domain (bZIP) mutations rather than double CEBPA mutations. We analysed 411 CEBPA ‐mutated AML patients from six Chinese centres, classified as single‐mutant CEBPA bZIP‐other (sm CEBPA bZIP‐other ; n = 38), sm CEBPA bZIP‐inf ( n = 39), double‐mutant CEBPA other (dm CEBPA other ; n = 37) and dm CEBPA bZIP‐inf ( n = 297). Dm CEBPA bZIP‐inf patients were younger, had more de novo AML and showed distinct co‐mutation profiles, with more GATA binding protein 2 ( GATA2 ) and fewer nucleophosmin 1 ( NPM1 )/DNA methyltransferase 3 alpha ( DNMT3A ) mutations. Additionally, dm CEBPA bZIP‐inf patients had a higher composite complete remission (CRc) rate (94.6% vs. 84.2%–89.2%, p = 0.025) and better survival than the other three groups (3‐year overall survival [OS]: 80.0% vs. 57.4%–70.6%, p < 0.001; 3‐year disease‐free survival [DFS]: 74.5% vs. 45.4%–67.9%, p = 0.002). Multivariable Cox regression analysis showed that dm CEBPA bZIP‐inf and sm CEBPA bZIP‐inf had comparable survival, whereas dm CEBPA bZIP‐inf had better survival than sm CEBPA bZIP‐other and dm CEBPA other . However, among intensively treated patients, dm CEBPA bZIP‐inf was associated with superior survival compared with sm CEBPA bZIP‐inf (OS, hazard ratio [HR] = 1.542, p = 0.017; DFS, HR = 1.618, p = 0.014) and other two CEBPA groups in multivariable models. Among dm CEBPA bZIP‐inf patients, intensive chemotherapy (HR = 0.51, p = 0.012), adverse karyotype (HR = 1.52, p = 0.037), age ≥50 years (HR = 1.74, p = 0.044), neuroblastoma RAS viral oncogene homolog ( NRAS ) (HR = 1.64, p = 0.014) and colony‐stimulating factor 3 receptor ( CSF3R ) mutation (HR = 1.78, p = 0.049) were independent factors for OS. No significant difference in survival was observed between patients with CEBPA bZIP‐indel and CEBP bZIP‐ms mutations. In conclusion, the dm CEBPA bZIP‐inf subgroup displayed unique co‐mutation gene spectra and had better prognoses among the intensive treated cohort.
No takes yet. Share an insight, caveat, or question.
Chang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: